Navigation Links
Chimerix to Present at Cowen and Company 31st Annual Health Care Conference

DURHAM, N.C., March 1, 2011 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at the Cowen and Company 31st Annual Health Care Conference on March 8, 2011, 1:30 pm ET, at the Boston Marriott Copley Place in Boston, Massachusetts. The Cowen and Company Health Care Conference is a conference for institutional investors focused on private and emerging public life science companies.

Mr. Moch will give an update on the company's pipeline and technology assets, including CMX001, a broad-spectrum antiviral being developed for the treatment of a wide range of infections caused by double-stranded DNA (dsDNA) viruses. CMX001 is in Phase 2 clinical studies in immunocompromised transplant and cancer patients for the prophylaxis and/or pre-emption of dsDNA viruses, including BK virus and adenovirus.  It is also undergoing an Open-Label study for the treatment of patients with any of 12 dsDNA infections which is designed to provide promising data for CMX001's fundamental studies.  In addition, CMX001 is being developed as a potential countermeasure in the event of a smallpox release.

About Chimerix and CMX001

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.

The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans.

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerix's extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies.

CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases under Grant No. UO1-AI057233, in addition to new funding from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201100013C.

Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.

Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerixs Lead Antiviral CMX001
2. Chimerix to Present at the Citi 2011 Global Health Care Conference
3. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
4. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
5. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
6. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
9. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
10. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
11. Chimerix to Present at Two Upcoming Investor Conferences
Post Your Comments:
(Date:11/30/2015)... -- --> --> According ... Product (Soft Tissue, All Tissue, Dental Welding Lasers), Application (Conservative ... - Global Forecast to 2020", published by MarketsandMarkets, is expected ... of 5.2% during the forecast period from 2015 to 2020. ... Figures spread through 167 P ages and in-depth TOC ...
(Date:11/30/2015)... and ST. LOUIS , Nov. ... (NASDAQ: ESRX ) today announced an early renewal ... which began in 1999, will now extend through at ... --> After evaluating pharmacy benefit manager capabilities during ... Express Scripts continues to offer the best health plan ...
(Date:11/30/2015)... , Nov. 30, 2015 Booth #4303 – ... VAR ) will exhibit a broader array of products in ... Radiological Society of North America in ... at the meeting will feature X-ray components "At the Heart ... a line of products from Varian,s Claymount brand, and computer-aided ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two ... American children and adults, according to a new study by researchers at the School ... in Children and Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers ...
(Date:11/30/2015)... ... ... Newly reviewed and approved “NJ Top Dentist”, Dr. Eugene Isola III, is ... in 1935. His father graduated from NYU School of Dentistry in 1965. ... their commitment and passion to the Practice of Dentistry. Continuing the family practice ...
(Date:11/30/2015)... New York, NY (PRWEB) , ... November 30, 2015 , ... ... New York Times,” will be released on December 1, 2015, to coincide with World ... book about the groundbreaking journalist who covered the AIDS epidemic as he was dying ...
(Date:11/30/2015)... ... November 30, 2015 , ... The American Society for ... honor of World AIDS Day 2015. On Nov. 30, ASCP shared its “Give a ... about World AIDS Day and the importance of getting tested for HIV. , ASCP ...
(Date:11/30/2015)... ... 30, 2015 , ... California-based i2i Systems, a pioneer defining ... Michigan-based Family Health Center (FHC) has selected i2iTracks as their population health management ... the largest Affordable Care Act grant for Federally Qualified Health Centers in the ...
Breaking Medicine News(10 mins):